Boeing secures $883 million Army contract for cargo support services
Autolus Therapeutics (NASDAQ:AUTL) stock has hit a 52-week low, dropping to $1.23, as the biopharmaceutical company faces a challenging market environment. According to InvestingPro data, despite the current market cap of $332.66M, analysts maintain price targets ranging from $6 to $14, suggesting potential upside. This new low underscores a significant downturn for the company, which has seen its stock value decrease by 77.16% over the past year. Investors are closely monitoring Autolus's performance, as the company navigates through a period of volatility and seeks to regain its footing in the competitive biotech industry. The 52-week low serves as a critical indicator for the company's short-term outlook and potential strategic adjustments moving forward. While the company maintains strong liquidity with a current ratio of 10.88 and more cash than debt on its balance sheet, InvestingPro analysis indicates the stock is currently undervalued, with 12 additional real-time insights available to subscribers.
In other recent news, Autolus Therapeutics reported a net loss of $220.7 million for the fourth quarter of 2024, which marked an increase from the $208.4 million loss in the previous year. Despite this, the company significantly bolstered its cash reserves to $588 million, primarily due to a $600 million collaboration with BioNTech (NASDAQ:BNTX) and equity financing. The ongoing launch of Autolus's Aucatzyl therapy for adult relapsed or refractory B-cell Acute Lymphoblastic Leukemia has seen the company exceed its initial target with 33 U.S. treatment centers authorized to administer the therapy, covering approximately 60% of the U.S. patient population. Analysts from Truist Securities have maintained their Buy rating on Autolus, highlighting robust demand for Aucatzyl despite potential initial uptake challenges. Meanwhile, Mizuho (NYSE:MFG) Securities reiterated its Outperform rating with a $12 price target following Autolus's recent earnings update. The company is also preparing for significant developments in 2025, including potential approval decisions for Aucatzyl in the UK and Europe and updates from its Phase 1 CARLYSLE trial. These updates, expected at Autolus's April research and development event, could provide insights into the initial efficacy and quality of their product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.